Latest KRAS Stories
Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.
Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs.
Researchers in the United States have shown, for the first time, that it is possible to screen cancer patients for a broad range of cancer-causing genetic mutations as part of normal clinical practice.
Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene.
- The word or words serving to define another word or expression, as in a dictionary entry.